Contact us
    First Immune - GcMAF
    Office Hours: 8:30am - 5:30pm (GMT)
    Clos de Balade 21, 1140 Evere, Brussels, Belgium
    Tel: +44 (0) 7781 411 737
    Fax: +44 (0) 1481 674 900
    Email: info@gcmaf.com

Three more research papers

We’ve just had three more peer reviewed research papers published in prestigious scientific journals. That makes 16 this year, easily a record by a GcMAF organisation.

They are:

Rather excitingly for those with ME/CFS, in the American Journal of Immunology, “Effects of GcMAF on human neurons and ME/CFS treatment.” Published the 8th November. This will, with our other discoveries, take our success with ME to above 70%.
And:

Group component protein-derived macrophage activating factor stimulates macrophages that induce human breast cancer cell apoptosis.
M. Ruggiero, L. Thyer, E. Ward, R. Smith, J.J.V. Branca, M. Gulisano, G. Morucci, S. Pacini.
Intl. J. Gynecol. Cancer. ECCO meeting abstr. 2013. Ovarian and Breast Cancer. P. 140.
and the third:

Vitamin D binding protein-derived macrophage activating factor inhibits human breast cancer cell proliferation and decreases alpha-N-acetyl galactosaminidase in breast cancer patiens
L. Thyer, G. Morucci, J.J.V. Branca, E. Ward, R. Smith, D. Noakes
Intl. J. Gynecol. Cancer. ECCO meeting abstr. 2013. Ovarian and Breast Cancer. P. 145.

Sorry comments are closed for this Post.

© 2013 First Immune - GcMAF All Rights Reserved | Site built by STRATAGEMdesign
go to top